242 related articles for article (PubMed ID: 27649770)
1. The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma.
Ellinger J; Gevensleben H; Müller SC; Dietrich D
Expert Rev Mol Diagn; 2016 Oct; 16(10):1059-1065. PubMed ID: 27649770
[TBL] [Abstract][Full Text] [Related]
2. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies.
Zeuschner P; Linxweiler J; Junker K
Expert Rev Mol Diagn; 2020 Feb; 20(2):151-167. PubMed ID: 31499007
[No Abstract] [Full Text] [Related]
3. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
Tusong H; Maolakuerban N; Guan J; Rexiati M; Wang WG; Azhati B; Nuerrula Y; Wang YJ
Cancer Biomark; 2017; 18(1):79-85. PubMed ID: 27814278
[TBL] [Abstract][Full Text] [Related]
4. Circulating Non-coding RNA as Biomarkers in Colorectal Cancer.
Ferracin M; Lupini L; Mangolini A; Negrini M
Adv Exp Med Biol; 2016; 937():171-81. PubMed ID: 27573900
[TBL] [Abstract][Full Text] [Related]
5. Detection Performance of Circulating MicroRNA-210 for Renal Cell Carcinoma: a Meta-Analysis.
Chen Y; Wang X; Zhu X; Shao S
Clin Lab; 2018 Apr; 64(4):569-576. PubMed ID: 29739083
[TBL] [Abstract][Full Text] [Related]
6. Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.
Fedorko M; Stanik M; Iliev R; Redova-Lojova M; Machackova T; Svoboda M; Pacik D; Dolezel J; Slaby O
Int J Mol Sci; 2015 Sep; 16(10):23382-9. PubMed ID: 26426010
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications.
Li M; Wang Y; Cheng L; Niu W; Zhao G; Raju JK; Huo J; Wu B; Yin B; Song Y; Bu R
Oncotarget; 2017 Jul; 8(29):48424-48435. PubMed ID: 28467794
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNAs and renal cell carcinoma.
Fedorko M; Febu ; Bohušová J; Poprach A; Pacík D
Klin Onkol; 2020; 33(5):340-349. PubMed ID: 33108878
[TBL] [Abstract][Full Text] [Related]
9. Circulating RNAs as new biomarkers for detecting pancreatic cancer.
Kishikawa T; Otsuka M; Ohno M; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jul; 21(28):8527-40. PubMed ID: 26229396
[TBL] [Abstract][Full Text] [Related]
10. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma.
Hauser S; Wulfken LM; Holdenrieder S; Moritz R; Ohlmann CH; Jung V; Becker F; Herrmann E; Walgenbach-Brünagel G; von Ruecker A; Müller SC; Ellinger J
Cancer Epidemiol; 2012 Aug; 36(4):391-4. PubMed ID: 22542158
[TBL] [Abstract][Full Text] [Related]
11. Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor Tissue, Blood Serum and Urine of Patients with Renal Cell Carcinoma.
Iliev R; Fedorko M; Machackova T; Mlcochova H; Svoboda M; Pacik D; Dolezel J; Stanik M; Slaby O
Anticancer Res; 2016 Dec; 36(12):6419-6423. PubMed ID: 27919963
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives.
Tsiakanikas P; Giaginis C; Kontos CK; Scorilas A
Expert Rev Mol Diagn; 2018 Nov; 18(11):981-991. PubMed ID: 30345829
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum-circulating RNA in patients with conventional renal cell cancer.
Feng G; Li G; Gentil-Perret A; Tostain J; Genin C
Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers.
Fedorko M; Pacik D; Wasserbauer R; Juracek J; Varga G; Ghazal M; Nussir MI
Int J Biol Markers; 2016 Feb; 31(1):e26-37. PubMed ID: 26481440
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic biomarkers in the blood of patients with urological malignancies.
Ellinger J; Müller SC; Dietrich D
Expert Rev Mol Diagn; 2015 Apr; 15(4):505-16. PubMed ID: 25719388
[TBL] [Abstract][Full Text] [Related]
16. Circulating adiponectin as a biomarker in renal cell carcinoma: a systematic review and meta-analysis.
Yap NY; Yap FN; Perumal K; Rajandram R
Biomarkers; 2019 Sep; 24(6):607-614. PubMed ID: 31215811
[No Abstract] [Full Text] [Related]
17. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies.
Cimadamore A; Massari F; Santoni M; Mollica V; Di Nunno V; Cheng L; Lopez-Beltran A; Scarpelli M; Montironi R; Moch H
Expert Rev Mol Diagn; 2020 Feb; 20(2):141-150. PubMed ID: 31498685
[No Abstract] [Full Text] [Related]
18. Circulating RNA in Kidney Cancer: What We Know and What We Still Suppose.
Cinque A; Vago R; Trevisani F
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071652
[TBL] [Abstract][Full Text] [Related]
19. Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring.
Crocetto F; Falcone A; Mirto BF; Sicignano E; Pagano G; Dinacci F; Varriale D; Machiella F; Giampaglia G; Calogero A; Varlese F; Balsamo R; Trama F; Sciarra A; Del Giudice F; Busetto GM; Ferro M; Lucarelli G; Lasorsa F; Imbimbo C; Barone B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612677
[TBL] [Abstract][Full Text] [Related]
20. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
